[go: up one dir, main page]

AU2003285686A8 - Glycoisoforms of adiponectin and uses thereof - Google Patents

Glycoisoforms of adiponectin and uses thereof

Info

Publication number
AU2003285686A8
AU2003285686A8 AU2003285686A AU2003285686A AU2003285686A8 AU 2003285686 A8 AU2003285686 A8 AU 2003285686A8 AU 2003285686 A AU2003285686 A AU 2003285686A AU 2003285686 A AU2003285686 A AU 2003285686A AU 2003285686 A8 AU2003285686 A8 AU 2003285686A8
Authority
AU
Australia
Prior art keywords
glycoisoforms
adiponectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003285686A
Other versions
AU2003285686A1 (en
Inventor
Garth J S Cooper
Aimin Xu
Yu Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
Protemix Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NZ2003/000002 external-priority patent/WO2003062275A1/en
Application filed by Protemix Corp Ltd filed Critical Protemix Corp Ltd
Publication of AU2003285686A8 publication Critical patent/AU2003285686A8/en
Publication of AU2003285686A1 publication Critical patent/AU2003285686A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003285686A 2002-12-23 2003-01-21 Glycoisoforms of adiponectin and uses thereof Abandoned AU2003285686A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US43614802P 2002-12-23 2002-12-23
US43617802P 2002-12-23 2002-12-23
NZ52341102 2002-12-23
NZ523410 2002-12-23
NZ523411 2002-12-23
NZ52341002 2002-12-23
US60/436,148 2002-12-23
US60/436,178 2002-12-23
NZNOTGIVEN 2003-01-17
PCT/NZ2003/000002 WO2003062275A1 (en) 2002-01-18 2003-01-17 Glycoisoforms of adiponectin and uses thereof
PCT/IB2003/006187 WO2004056861A2 (en) 2002-12-23 2003-01-21 Glycoisoforms of adiponectin and uses thereof

Publications (2)

Publication Number Publication Date
AU2003285686A8 true AU2003285686A8 (en) 2004-07-14
AU2003285686A1 AU2003285686A1 (en) 2004-07-14

Family

ID=32686197

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003285686A Abandoned AU2003285686A1 (en) 2002-12-23 2003-01-21 Glycoisoforms of adiponectin and uses thereof

Country Status (2)

Country Link
AU (1) AU2003285686A1 (en)
WO (1) WO2004056861A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324234A (en) 1998-09-25 2001-11-28 格利科克斯有限公司 Fructosamine oxidase: antagonists and inhibitors
WO2003077901A1 (en) 2002-03-08 2003-09-25 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
CA3011023A1 (en) 2002-08-20 2004-03-04 Philera New Zealand Limited Composition comprising triethylenetramine salts for treating tissue damage
CA3050047A1 (en) 2004-07-19 2006-03-16 Philera New Zealand Limited Synthesis of triethylenetetramines
EP1830873A4 (en) 2004-12-10 2008-04-02 Protemix Corp Ltd GLYPONECTIN (ADIPONECTIN GLYCOSYLE) FOR THE TREATMENT OF DISEASES AND CONDITIONS
WO2006104964A2 (en) * 2005-03-28 2006-10-05 University Of Louisville Research Foundation, Inc. Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30
CN103041371A (en) * 2012-12-31 2013-04-17 上海市内分泌代谢病研究所 Application of adiponectin in preparing medicine for curing cerebral arterial thrombosis of old people
WO2020201195A2 (en) * 2019-04-04 2020-10-08 Bayer Aktiengesellschaft Agonists of adiponectin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547696B2 (en) * 2001-06-07 2010-09-22 第一三共株式会社 Cirrhosis prevention / treatment agent
WO2003062275A1 (en) * 2002-01-18 2003-07-31 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof

Also Published As

Publication number Publication date
WO2004056861A2 (en) 2004-07-08
WO2004056861A3 (en) 2004-09-30
AU2003285686A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
EP1474445A4 (en) Glycoisoforms of adiponectin and uses thereof
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
EP1549614A4 (en) Vasculostatic agents and methods of use thereof
AU2003288902A8 (en) Microcapsules and methods of use
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1539941A4 (en) Adzymes and uses thereof
PL375691A1 (en) Imidazolopyridines and methods of making and using the same
AU2003259735A8 (en) Small-mer compositions and methods of use
AU2003295801A8 (en) Modulation of hif1alpha and hif2alpha expression
AU2003259717A8 (en) Modulators of rabggt and methods of use thereof
AU2003299441A8 (en) Nf-hev compositions and methods of use
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
AU2003272442A8 (en) Electroactive microspheres and methods
AU2003296369A8 (en) Imminoamines and preparation thereof
SI1551805T1 (en) Substituted gamma-phenyl-delta-lactams and uses related thereto
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003285686A8 (en) Glycoisoforms of adiponectin and uses thereof
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003216354A8 (en) Modulators of paraptosis and related methods
AU2003296871A8 (en) Point feeder and use of point feeder
AU2003282593A8 (en) Polyphenolamine composition and method of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase